Randomized, double-blind, parallel-group, multicenter, 24-week trial to evaluate the efficacy and safety of budesonide and formoterol fumarate metered-dose inhaler compared to budesonide metered-dose inhaler and Symbicort® open-arm Turbohaler® pressurized metered dose inhaler in patients with poorly controlled asthma (VATHOS).
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ASTRAZENECA FARMACEUTICA ESPAÑA SA
- Phase: III
- Execution start: 10/06/2022
- End of execution: 30/11/2023
- IP: CONCEPTION MORALES GARCIA
